By Tracy Staton The shake-up at the top of Salix Pharmaceuticals continues. On Monday afternoon, CEO Carolyn Logan became the second C-suite executive to step down in the wake of an inventory snafu disclosed late last year. Logan will retire as of Jan. 30, the company said. CFO Adam Derbyshire made his exit in [...]
GSK - NYSE - Nasty Chart, looks like a test of the 2012 low is coming. GlaxoSmithKline ($GSK) is making big cost cuts to boost its finances next year as sales of its $8.25 billion asthma med Advair are deflated by competition, generic and otherwise. With the U.S. being the biggest market for the [...]
Since its lows in mid-October, biotech stocks have sparkled, particularly the Big four – Amgen (AMGN), Biogen Idec (BIIB), Celgene (CELG), and Gilead (GILD) – which have demonstrated sustainable growth pathways. With the market’s renewed volatility in recent days, they have pulled back some, which only made them much more reasonably priced. But the more [...]
We have bad news and good news about patent expirations next year. The bad? When you tot up the billions of sales at risk of patent expiration in 2015, the result is $44 billion, the biggest number since the debacle of 2012. That year, $53 billion worth of drugs fell off patent--and many drugmakers are [...]
Tony Coles, the chief executive who sold Onyx Pharmaceuticals to Amgen AMGN -2.45% for $10.4 billion in 2013, is starting a new company that will use yeast to try and discover new treatments for Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease.) The new startup, Yumanity, will be based in [...]
Teva stalled out? Maybe? Like the rest of the space, TEVA has had a nice ride, but maybe time to step aside. See the article and chart. Don't be surprised if Teva's ($TEVA) revenue numbers don't meet analysts' expectations in 2015. According to the company's forecasts, generic competition to top-seller Copaxone and foreign currency [...]
Drugmakers that complain about the growing cost to bring new molecular entities to market aren’t exaggerating, according to a study released last month by the Tufts Center for the Study of Drug Development (CSDD). Even with the initiation of mechanisms to speed drug development such as breakthrough therapy designation and accelerated review, developing a medicine [...]
In partnership with activist investor Bill Ackman, the company made a hostile bid to purchase Botox-maker Allergan. Valeant Pharmaceuticals is putting its acquisition growth strategy on hold in favor of reducing debt and boosting its stock price, according to Reuters. Since 2008, Valeant has spent about $19 billion on 40 acquisitions. Now, the company will [...]
Studyops, San Francisco, CA. 11/26/2014, and the Center for Occupational Health received an award for a new RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED Clinical Trial for patients with Fibromyalgia. Dr Viladimir Bokarius will be the lead principal investigator for the project, which will take place in our Richmond California location. Studyops continues to be the Sponsor's choice [...]
http://www.fiercepharma.com/story/takedas-us-chief-bows-out-amid-management-shake/2014-11-25?utm_medium=nl&utm_source=internal Takeda Chief is out, EVP Lise Kingo at Novo is out, Allergan pruning the Executive offices, plenty of others. All the M&A buys pipelines, but surely does not guarantee FDA follow through. www.studyops.com
